PTCE Pharmacy Connect | Pharmacy Times

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patie...

Educational Objectives Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence   Faculty Lauren Ledbetter, PharmD, BCOP Clinical Pharmacy Specialist, Thoracic Medical Oncology The James Cancer Hospital at The Ohio State University...

Educational Objectives Review challenges that impact optimal treatment of skin barrier dysfunction in patients with acne who are seeking OTC care List strategies to individualize patient care and improve recommendations for patients with acne experiencing skin barrier dysfunction Faculty: Robin Laird Patient Advocate Los Angeles, California   Mary Barna Bridgeman, PharmD, BCPS, BCGP Clinical Profe...

  Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Title: Challenges in Treatment of Desmoid Tumors and Managed Care Solutions Ed...

To claim CE credit for this activity, please follow this link:  www.pharmacytimes.org/atopic-derm-podcast-630 Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailor...

Educational Objectives Outline the place in therapy for targeted therapies based on patient-specific factors and subtype of early-stage breast cancer Recognize methods to improve patient treatment selection while mitigating toxicities in patients with early-stage breast cancer Faculty: Allison R. Butts, PharmD, BCOP Pharmacist Manager, Oncology Breast Oncology Clinical Pharmacy Specialist Acute Ca...

Educational Objectives Recall the pathophysiology and clinical manifestations of Duchenne muscular dystrophy (DMD), as well as the burden of DMD and its impact on patient quality of life List the latest updates for the safety and efficacy data of new and approved disease-modifying therapies in the treatment of DMD   Faculty: Amanda Hickman, PharmD, MPH, MSCS Central Support Pharmacist – Neuro/Psyc...

Educational Objective: Outline various challenges and uncertainties affecting the optimization of treatment with novel immunotherapeutic modalities for relapsed/refractory diffuse large B-cell lymphoma.   Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist - Hematology University of Michigan Rogel Cancer Center Ann Arbor, Michigan   Moderator: Laura R. Bobolts, PharmD, BCOP SVP,...

Educational Objectives Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP) Recall the efficacy and safety of emerging agents for the treatment of ITP   Moderator: Anthony J. Perissinotti, PharmD, BCOP To claim CE credit for this activity, please visit the link below: https://www.pharmacytimes.org/courses/advances-in...

The educational objectives are: • Review the pathophysiology of atopic dermatitis (AD) as well as the efficacy and safety data for topical JAK inhibitors that are approved and in development • Discuss the role of pharmacists as a part of the care team for patients with AD as well as the key counseling points and monitoring parameters   Faculty: Dennis Williams Moderator: Jamie McConaha

Educational Objectives Discuss the differing classes of B-cell maturation antigen-directed therapy for multiple myeloma Study the economic burden of multiple myeloma and cost-effective treatment strategies for B-cell maturation antigen-directed treatments Faculty: Joseph A. Kalis, PharmD, BCOP Ambulatory Oncology Pharmacist UCHealth Hematology/Oncology Colorado Springs, Colorado   Scott A. Soefje,...

Introduction of moderator, faculty, and disclosures by Todd: ­We have an incredible discussion coming up with our moderator, Dr. Jessica Kerr, Professor and Clinical Pharmacy Specialist – Cardiometabolic at the Southern Illinois University Edwardsville School of Pharmacy in Illinois and Dr. Joanna Hudson, who is a tenured Professor in the Department of Clinical Pharmacy and Translational Science a...

Introduction of faculty and disclosures:  Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia. Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi. Accreditation and support statement:  PTCE i...

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. The Managed Care Implications of Cost, Disease Burden, and Quality of Life in My...

Educational Objective: Outline the standard treatment options for myelofibrosis as well as review clinical data for Janus kinase inhibitors and emerging targeted therapies.     Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Hematology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan     Victoria Na...

Educational Objective: Review the etiology and pathophysiology of myelofibrosis, including the World Health Organization classification and diagnostic criteria.     Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Hematology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan   Victoria Nachar, PharmD,...

Accreditation and support statement: ·   PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. ·   This activity is supported by educational grant from GlaxoSmithKline. Objectives •   Review the guideline-recommended role of immune-based therapies in th...

 Educational Objectives ·      Discuss currently available options for pre-exposure prophylaxis (PrEP) in the prevention of HIV. ·      Describe the role of pharmacists in improving PrEP uptake in the United States.      Faculty: Drew W. Cates, PharmD, AAHIVP, Educational Manager SynerGrx Chamblee, Georgia  Faculty, has the following financial relationships with commercial interests to disclose: S...

Educational Objectives Objective 1: Describe a strategy to mitigate potential adverse effects of MM therapies by altering the route of administration, dosing schedule, and use of supportive care medications   Kathryn Maples, PharmD, BCOP Clinical Pharmacy Specialist, Multiple Myeloma Winship Cancer Institute, Emory Healthcare Atlanta, Georgia   Kathryn Maples, PharmD, BCOP, has the following relev...

Educational Objectives • Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC) • Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations   Josiah D. Land, PharmD, BCOP Clinical Pharmacy Specialist – Th...

Educational Objectives ·      Review the efficacy and safety of emerging frontline immune checkpoint inhibitor (ICI) used as monotherapy and in combination regimens ·      Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient reported outcomes related with frontline use of ICIs in advanced NSCLC   Faculty: Paul Forsberg, PharmD, MHA, BCOP Director of P...

Introduction of faculty and disclosures:  Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia. Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi. Accreditation and support statement:  PTCE i...

Educational Objectives ·      Understand the impact of Janus kinase inhibitors for the management of atopic dermatitis (AD) ·      Examine key safety and efficacy data on new and emerging Janus kinase inhibitors utilized for the treatment of AD and select appropriate treatments Identify the role of the pharmacist in individualizing treatment for patients with AD through patient counseling and educ...

Educational Objectives ·      Recognize the role of biomarker expression in the selection of most appropriate treatment options for patients with endometrial cancer ·      Review strategies for identification and management of drug-related toxicities in patients receiving therapy with immune checkpoint inhibitors, targeted agents, or combination therapy    Faculty: Sarah Hayward, PharmD, BCOP Clin...

Introduction of faculty and disclosures:  Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida. Dr. Tobon has no relevant financial relationships with commercial interests to disclose. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing p...